SAN DIEGO--(BUSINESS WIRE)--Artes Medical, Inc. (Nasdaq:ARTE), a medical aesthetics company, today announced that enrollment has been completed in the 1,000-patient post-marketing study required by the FDA. The study follows patients treated with ArteFill®, the first and only FDA-approved non-resorbable dermal filler, for a five-year period.
